[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$ttiv
Thiogenesis is dosing patients in a Euro Phase X trial for TTI-0102. Interim efficacy readout expected this fall.
About $ttiv
A biotechnology company focused on developing treatments for Leigh Syndrome and MELAS.
Engagements: XXX #
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XXX
1 Month: XXX +493%
1-Year High: XXXXX on 2025-05-05
1-Year Low: X on 2025-05-10
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X -XX%
1 Month: X +700%
1-Year High: X on 2025-05-11
1-Year Low: X on 2025-05-05
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $ttiv in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1 Week: X no change
1 Month: X +200%
1-Year High: X on 2025-05-06
1-Year Low: X on 2025-05-05
Top topics mentioned In the posts about $ttiv in the last XX hours
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Estimated at $273M in 2025 & projected to hit $436M by 2032 the Leigh Syndrome treatment market is wide open. With no approved therapies @thiogenesis is dosing patients in a Euro Phase X trial for TTI-0102. More info 🔽 $TTI.v $TTIPF Market Source:"
@StckMasterFlash on X 2025-07-25 20:17:50 UTC 2902 followers, XXX engagements
"In a market projected to grow to nearly half a billion dollars by 2035 @thiogenesis is dosing patients in its EU Phase X trial for TTI0102 targeting the underlying antioxidant deficiencies in MELAS. Interim efficacy readout expected this fall. More Info🔽 $TTI.v $TTIPF Source:"
@StckMasterFlash on X 2025-07-23 21:04:45 UTC 2902 followers, XX engagements